Mimicking liver metabolism for drug discovery
This article was originally published in Start Up
Liver toxicity is the most common safety issue in new drug development. Unfortunately, existing techniques for identifying drug metabolites aren’t that reliable. As a result, drugs frequently enter clinical trials with relatively little or no metabolite data that might alert developers to potential safety problems. HepatoChem Inc. aims to improve matters for its clients with a “chemical liver” designed to mimic the oxidation that can occur during Phase I metabolism.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.